Sugi Predict

Sugi Predict / Compounds / SCHEMBL659422

SCHEMBL659422

SCHEMBL659422

COc1cc(C(=O)ONS(=O)(=O)C(=O)c2ccccc2C)ccc1Cn1ncc2ccc(Nc3ncc(F)c(Nc4ccc(OC(C)C)cc4)n3)cc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SYK P43405 11/20 0.47
▸ CYSLTR2 Q9NS75 1/20 0.39
▸ CYSLTR1 Q9Y271 1/20 0.39
▸ AURKA O14965 5/20 0.37
▸ PLK4 O00444 1/20 0.37
▸ PDPK1 O15530 1/20 0.37
▸ DAPK3 O43293 1/20 0.37
▸ JAK2 O60674 1/20 0.37
▸ MAP4K4 O95819 1/20 0.37
▸ PAK4 O96013 1/20 0.37
▸ CHEK2 O96017 1/20 0.37
▸ EGFR P00533 1/20 0.37
▸ ERBB2 P04626 1/20 0.37
▸ NTRK1 P04629 1/20 0.37
▸ PRKCG P05129 1/20 0.37
▸ INSR P06213 1/20 0.37
▸ LCK P06239 1/20 0.37
▸ FYN P06241 1/20 0.37
▸ CDK1 P06493 1/20 0.37
▸ CSF1R P07333 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1116425 0.91 SYK (0.48) SYKCYSLTR2CYSLTR1AURKAPLK4
SCHEMBL657271 0.90 SYK (0.49) SYKCYSLTR2CYSLTR1AURKAMAPK8
SCHEMBL3091493 0.88 SYK (0.47) SYKCYSLTR2CYSLTR1EGFRBTK
SCHEMBL656995 0.86 SYK (0.56) SYKAURKAMAPK8AURKB
SCHEMBL656843 0.84 SYK (0.53) SYKEGFRBTK
SCHEMBL1116431 0.81 SYK (0.51) SYKCYSLTR2CYSLTR1AURKA
SCHEMBL657417 0.79 CYSLTR2 (0.44) CYSLTR2CYSLTR1
SCHEMBL656612 0.79 SYK (0.47) SYKCYSLTR2CYSLTR1EGFRBTK
SCHEMBL658051 0.76 SYK (0.60) SYKAURKA
SCHEMBL1116428 0.76 SYK (0.57) SYKAURKAEGFRITK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9416112-B2 2,4-pyrimidinediamine compounds and their uses RIGEL PHARMACEUTICALS, INC. (US) 2016-08-16 — — US disclosed
US-9133133-B2 2,4-pyridinediamine compounds and their uses RIGEL PHARMACEUTICALS, INC. (US) 2015-09-15 — — US disclosed
US-9040550-B2 2,4-pyrimidinediamine compounds and their uses RIGEL PHARMACEUTICALS, INC. (US) 2015-05-26 — — US disclosed
US-20150126504-A1 2,4-Pyrimidinediamine Compounds and Their Uses RIGEL PHARMACEUTICALS, INC. (US) 2015-05-07 — — US disclosed
US-20150005297-A1 2,4-Pyrimidinediamine Compounds and Their Uses RIGEL PHARMACEUTICALS, INC. (US) 2015-01-01 — — US disclosed
US-20140330007-A1 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES RIGEL PHARMACEUTICALS, INC. (US) 2014-11-06 — — US disclosed
US-20140303154-A1 2,4-PYRIDINEDIAMINE COMPOUNDS AND THEIR USES RIGEL PHARMACEUTICALS, INC. (US) 2014-10-09 — — US disclosed
US-8853397-B2 2,4-pyrimidinediamine compounds and their uses Rigel Pharmacuticals, Inc. (US) 2014-10-07 — — US disclosed
US-8835430-B2 2,4-pyrimidinediamine compounds and their uses RIGEL PHARMACEUTICALS, INC. (US) 2014-09-16 — — US disclosed
US-8822685-B2 2,4-pyrimidinediamine compounds and their uses RIGEL PHARMACEUTICALS, INC. (US) 2014-09-02 — — US disclosed
US-8410266-B2 2,4-pyrimidinediamine compounds and their uses RIGEL PHARMACEUTICALS, INC. (US) 2013-04-02 — — US disclosed
US-8334296-B2 2,4-pyrimidinediamine compounds and their uses RIGEL PHARMACEUTICALS, INC. (US) 2012-12-18 — — US disclosed
US-8188276-B2 2,4-pyrimidinediamine compounds and their uses RIGEL PHARMACEUTICALS, INC. (US) 2012-05-29 — — US disclosed
US-20120045454-A1 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES RIGEL PHARMACEUTICALS, INC. 2012-02-23 — — US disclosed
US-7803939-B2 N2,N4-bis(4-ethoxyphenyl)-5-fluoro-2,4-pyrimidinediamine; inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators; Syk kinase inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2010-09-28 — — US disclosed
US-7655797-B2 reacting a aminobenzoxazne or aminobenzothiazine or aminobenzodithiazine compounds wtih 2,4-dichloro-5-fluoropyrimidine to form 2,4-pyrimidinediamne compound; used to inhibit IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators; antiinflammatory agent, antiallergen RIGEL PHARMACEUTICALS, INC. (US) 2010-02-02 — — US disclosed
US-20090171085-A1 N2,N4-bis(4-ethoxyphenyl)-5-fluoro-2,4-pyrimidinediamine; inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators; Syk kinase inhibitors RIGEL PHARMACEUTICALS, INC. 2009-07-02 — — US disclosed
US-20090171086-A1 inhibitors of immunoglobulin E or G receptor signaling cascades; Syk kinase inhibitors; use as antiallergic, antiinflammatory agents RIGEL PHARMACEUTICALS, INC. 2009-07-02 — — US disclosed
US-20090156622-A1 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES RIGEL PHARMACEUTICALS, INC. 2009-06-18 — — US disclosed
US-20090082567-A1 reacting a aminobenzoxazne or aminobenzothiazine or aminobenzodithiazine compounds wtih 2,4-dichloro-5-fluoropyrimidine to form 2,4-pyrimidinediamne compound; used to inhibit IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators; antiinflammatory agent, antiallergen RIGEL PHARMACEUTICALS, INC. 2009-03-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120045454-A1 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES FCER2, FCGR1A, FCGR2A SYK 54/4885CYSLTR2 15/4885CYSLTR1 19/4885
US-20140303154-A1 2,4-PYRIDINEDIAMINE COMPOUNDS AND THEIR USES FCER2, FCGR1A, FCGR2A SYK 38/4885CYSLTR2 8/4885CYSLTR1 15/4885
US-20150005297-A1 2,4-Pyrimidinediamine Compounds and Their Uses FCER2, FCGR1A, FCGR2A SYK 54/4885CYSLTR2 15/4885CYSLTR1 19/4885
US-20090156622-A1 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES FCER2, FCGR1A, FCGR2A SYK 54/4885CYSLTR2 15/4885CYSLTR1 19/4885
US-20150126504-A1 2,4-Pyrimidinediamine Compounds and Their Uses FCER2, FCGR1A, FCGR2A SYK 54/4885CYSLTR2 15/4885CYSLTR1 19/4885
US-20140330007-A1 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES FCER2, FCGR1A, FCGR2A SYK 54/4885CYSLTR2 15/4885CYSLTR1 19/4885
US-20090171085-A1 N2,N4-bis(4-ethoxyphenyl)-5-fluoro-2,4-pyrimidinediamine; inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators; Syk kinase inhibitors FCER2, FCGR1A, SYK SYK 3/4885CYSLTR2 31/4885CYSLTR1 40/4885
US-20090082567-A1 reacting a aminobenzoxazne or aminobenzothiazine or aminobenzodithiazine compounds wtih 2,4-dichloro-5-fluoropyrimidine to form 2,4-pyrimidinediamne compound; used to inhibit IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators; antiinflammatory agent, antiallergen HRH2, HRH1, FCER2 SYK 71/4885CYSLTR2 23/4885CYSLTR1 40/4885
US-20090171086-A1 inhibitors of immunoglobulin E or G receptor signaling cascades; Syk kinase inhibitors; use as antiallergic, antiinflammatory agents FCER2, SYK, FCGR1A SYK 2/4885CYSLTR2 21/4885CYSLTR1 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.